Professor, Medicine, Tulane University Sch of Med
Cardiology
Dr. Gary E. Sander, MD
|
|
Give Review
Dr. Gary E. Sander is an expert in the field of Cardiology. He went to Tulane University School of Medicine. He over the years received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Fellow (FACC)". Gary Sander is also a published MD. He has 81 publication published. The most recent publication is: Relationship between resting metabolic rate and the composition of the fat-free mass. He is registered with Medicare and accepts Medicare payments.
Publications
- Nebivolol and valsartan as a fixed-dose combination for the treatment of Hypertension.
- The New International Classification of Diseases (ICD-10): The Hypertension Community Needs a Greater Input.
- What Is the Blood Pressure Goal for the Elder Patient 75 Years of Age or Older?
- Resistant Hypertension: concepts and approach to management.
- The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in Hypertension.
- Thiazide Diuretics and β-Blockers in the Treatment of Hypertension in Diabetes Mellitus.
- ECG of the month. Bigeminal rhythm VI.
- Atorvastatin induced multiple organ Failure.
- Effects of thiazolidinediones on blood pressure.
- The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions.
- The need for defining- and redefining- Hypertension: beyond the numbers.
- Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic Syndrome.
- Medical management of Myocardial ischemia.
- Alcohol--a cardiovascular drug?
- Diabetes mellitus and Heart failure: basic mechanisms, clinical features, and therapeutic considerations.
- Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
- Ximelagatran: light at the end of the tunnel or the next tunnel?
- ALLHAT and ANBP2: what have we learned from recent mega-trials?
- Statin therapy in the elderly-the evidence mounts.
- Hypertension and lipids: lipid factors in the hypertension Syndrome.
- HOPE in PROGRESS--a tale of two trials: blood pressure reduction or drug mechanism?
- Noncardiac drugs and QTc interval prolongation: an often unrecognized risk factor for adverse cardiovascular outcomes.
- Cardiovascular Complications of Collagen Vascular Disease.
- Angiotensin II (AT(1)) receptor antagonists, diabetes, and nephropathy: do differences between the renal and systemic circulations explain the outcomes observed with A...
- Aspects of the Use of Angiotensin-Converting Enzyme Inhibitors and Calcium Antagonists in Treatment of Heart Failure in the Older Patient.
- Stress Cardiomyopathy in the Setting of COPD Exacerbation.
- Relationship between resting metabolic rate and the composition of the fat-free mass.
- Leucine-enkephalin: reversal of intrinsic cardiovascular stimulation by pentobarbital.
- Quaternary opiate antagonists lower blood pressure and inhibit leucine-enkephalin responses.
- Interactions of leucine-enkephalin with alpha-adrenoceptors in the conscious dog.
- CardioPulmonary pharmacology of enkephalins in the conscious dog.
- Enkephalin analogs and dermorphin in the conscious dog: structure-activity relationships.
- Elevation of arterial blood pressure in conscious dogs by Des-Tyr1-D-Ala2-leucine-enkephalinamide.
- Cardiovascular interactions between methionine-enkephalin and substance P in the conscious dog.
- The effects of barbiturates upon the hemodynamic responses to intravenous methionine-enkephalin in dogs: modulation by the GABA complex.
- Ventilatory response to intravenous methionine enkephalin in awake dogs.
- Central alpha-adrenergic agonists in chronic Heart failure and ischemic Heart disease.
- Mechanism of the cardiovascular response to systemic intravenous administration of leucine-enkephalin in the conscious dog.
- MIF-1 does not act like naloxone in antagonizing the cardiovascular activity of leucine-enkephalin in the conscious dog.
- Non-opiate and peripheral-opiate cardiovascular effects of morphine in conscious dogs.
- Comparative cardiovascular responses to intravenous capsaicin, phenyldiguanide, veratrum alkaloids and enkephalins in the conscious dog.
- Methionine-enkephalin does not alter human platelet aggregatory response.
- Cardiovascular activities of intravenous methionine-enkephalin-Arg6-Phe7 and methionine-enkephalin-Arg6-Gly7-Leu8 in the conscious dog.
- Systemic methionine-enkephalin evokes cardiostimulatory responses in the human.
- Evidence for Des-Tyr1-D-Ala2-leucine5-enkephalinamide calcium agonist activity in vascular smooth muscle.
- The effect of intravenous clonidine hydrochloride on the isolated forearm venous segment in Heart failure.
- Methionine-enkephalin facilitates the cardiovascular response to epinephrine in the conscious dog.
- The influence of the inter-dose time interval on the cardiovascular response to methionine-enkephalin in the conscious dog.
- Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phe...
- AntiAnginal effects of clonidine.
- Alpha-adrenergic mechanisms in the pathophysiology of left ventricular Heart failure--an analysis of their role in systolic and diastolic dysfunction.
- Comparison of nitrendipine and hydrochlorothiazide for systemic Hypertension.
- Nifedipine-associated Myocardial ischemia or infarction in the treatment of hypertensive urgencies.
- Acute and short-term effects of clonidine in Heart failure.
- Interactions between circulating peptides and the central nervous system in hemodynamic regulation.
- Time-dependent antiHypertensive effect of carteolol--a beta-adrenoceptor antagonist with partial agonist activity.
- Failure of interleukin-2 to alter systolic blood pressure in Dahl salt-sensitive rats.
- N-allylnormetazocine: hemodynamic actions and inhibition of leucine-enkephalin hemodynamic activity in conscious dogs.
- The effect of area postrema lesions on hemodynamic responses to systemic methionine-enkephalin in conscious dogs.
- Acute hypotension alters hemodynamic response to methionine-enkephalin in conscious dogs.
- Endothelin produces systemic vasodilation independent of the state of consciousness.
- Intravenous captopril in congestive Heart failure.
- Carteolol, an antiHypertensive beta-blocker with intrinsic sympathomimetic activity, reduces ECG evidence of left ventricular hypertrophy.
- Hemodynamic actions of endothelin in conscious and anesthetized dogs.
- Prolonged hemodynamic benefits from a high-dose bolus injection of human atrial natriuretic factor in congestive Heart failure.
- Myocardial Disease in hypertensive-diabetic patients.
- Preservation of left ventricular function and Coronary flow by angiotensin I-converting enzyme inhibition in the hypertensive-diabetic Dahl rat.
- Remission of mild to moderate Hypertension after treatment with carteolol, a beta-adrenoceptor blocker with intrinsic sympathomimetic activity.
- Reawakening of interest in aldosterone and aldosterone antagonists: implications for treatment of cardiovascular Disease.
- High blood pressure in the geriatric population: treatment considerations.
- Comparative effects of nitrendipine and hydrochlorothiazide on calciotropic hormones and bone density in Hypertensive patients.
- Efficacy of nicardipine in Angina pectoris.
- Circadian variation in blood pressure and Heart rate in nonhypertensive congestive Heart failure.
- Comparison of effects of nitrendipine versus hydrochlorothiazide on left ventricular structure and function and neurohumoral status in systemic Hypertension.
- Atrial fibrillation in the elderly--an increasing problem that mandates aggressive management.
- Heart failure in diabetes mellitus: causal and treatment considerations.
- Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of Heart failure caused by left ventricular systolic dysfunction.
- Beyond the usual strategies for blood pressure reduction: therapeutic considerations and combination therapies.
- Angiotensin II receptor (AT1) antagonists in Heart failure after Val-HeFT--Quo Vadis?
- Histologically measured cardiomyocyte hypertrophy correlates with body height as strongly as with body mass index.
Schools
Tulane University School Of Medicine
Walter Reed Army Med Center
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac Myocardial Perfusion Imaging
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACC)
Education
-
Tulane University School of Medicine
Drug Facts
| NPI NUMBER | 1538125174 | |
| NPPES Provider LastName | SANDER | |
| NPPES Provider FirstName | GARY | |
| NPPES Provider ZIPCode | 701196302 | |
| NPPES Provider State | LA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 1586.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 0.88 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1538125174 |
| Last Name Of The Provider | SANDER |
| First Name Of The Provider | GARY |
| View All |
Similar Doctors
|
|
Dr. Sylvia A. Oleck, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Freddy M. Abi-Samra, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. David A. Liff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Krishna K. Gaddam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald S. Berenson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert M. Pinner, MD |
|
Dr. Tyrone J. Collins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thierry H. Lejemtel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elias B. Hanna, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Stacey E. Ducombs-Isa, APRN
This Doctor is OpenDoctor Recommended.
|